Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

IVERIC bio, Inc. ISEE NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
26/100
0/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$32.75
-18%

IVERIC bio, Inc. (ISEE) is a Biotechnology company in the Healthcare sector, currently trading at $39.95. It has a SharesGrow Score of 26/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Analyst consensus target is ISEE = $33 (-18% upside).

Net income is $176M (loss), growing at -44.2%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $98M against $535M equity (Debt-to-Equity (D/E) ratio 0.18, conservative). Current ratio is 18.63 (strong liquidity). Debt-to-assets is 14.7%. Total assets: $667M.

Analyst outlook: 9 / 24 analysts rate ISEE as buy (38%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 20/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 40/100 (Fail), Future 16/100 (Fail), Income ?/100 (Fail).

$32.75
▼ 18.02% Downside
Average Price Target
Based on 24 Wall Street analysts offering 12-month price targets for IVERIC bio, Inc., the average price target is $32.75, with a high forecast of $35.00, and a low forecast of $27.00.
Highest Price Target
$35.00
Average Price Target
$32.75
Lowest Price Target
$27.00

ISEE SharesGrow Score Overview

32/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 20/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 40/100
Gross margin is + market cap
FUTURE 16/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ISEE

✗
VALUE Fail
20/100
ISEE trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $33, implying -17.4% from the current price $40. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
ISEE: +0%/yr revenue is, -44.2%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet ISEE: Debt-to-Equity (D/E) ratio 0.18 (conservative), Current ratio is 18.63 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
40/100
ISEE: Gross margin is 0% (+0 pp trend), $6B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 40/100. ≥ 70 = Pass.
View details →
✗
FUTURE Fail
16/100
Analyst outlook: 9 / 24 analysts rate ISEE as buy (38%). Analyst consensus target is $33 (-17.4% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range9.39-39.99
Volume10.8M
Avg Volume (30D)4.95M
Market Cap$5.51B
Beta (1Y)1.10
Share Statistics
EPS (TTM)-1.45
Shares Outstanding$121.04M
IPO Date2013-09-25
Employees163
CEOGlenn P. Sblendorio
Financial Highlights & Ratios
EBITDA$-192.28M
Net Income$-175.75M
Operating Income$-189.91M
Total Cash$646.84M
Total Debt$97.77M
Net Debt$-378.54M
Total Assets$666.82M
Price / Earnings (P/E)-27.6
Analyst Forecast
1Y Price Target$34.50
Target High$35.00
Target Low$27.00
Upside-13.6%
Rating ConsensusHold
Analysts Covering24
Buy 38% Hold 58% Sell 4%
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS46583P1021

Price Chart

Track all markets on TradingView
ISEE
IVERIC bio, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
9.39 52WK RANGE 39.99

People Also View

ROIV
ROIV
Roivant Sciences Ltd.
$29.12
+0.59%
 KRTX
KRTX
Karuna Therapeutics, Inc.
$329.83
+0.03%
 MDGL
MDGL
Madrigal Pharmaceuticals, Inc.
$524.99
-0.13%
 RXDX
RXDX
Prometheus Biosciences, Inc.
$199.92
+0.09%
 BPMC
BPMC
Blueprint Medicines Corporation
$129.46
+0.14%
 KRYS
KRYS
Krystal Biotech, Inc.
$270.00
+0.97%
 ACLX
ACLX
Arcellx, Inc.
$114.89
+0.02%
 RETA
RETA
Reata Pharmaceuticals, Inc.
$172.36
+0.02%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message